Navigation Links
Arable Corporation Announces New Technology for Clinical Trial Industry
Date:10/11/2010

PALO ALTO, Calif., Oct. 11 /PRNewswire/ -- Arable Corporation (www.arablecorp.com) has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry.  Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS and EDC capabilities without the traditionally high start-up costs.

The Arable Perform platform allows Sponsors or CROs to manage the planning and implementation of multiple trials simultaneously.  Perform also provides large Sites with the ability to manage their service delivery to multiple CROs or Sponsors.  With Perform's proprietary dashboard, stakeholders and managers are able to view real-time status of trials down to the site or subject visit.

"Our new Arable Perform platform allows us to offer our clients immediate access to clinical trial software with the shortest "Go Live" time in the industry and at a reasonable cost," stated Ary Sarkar, CEO of Arable Corporation.  "At Arable, we combine our knowledge of the clinical trial space with our technology partnerships to offer our clients a range of services from trial planning and implementation through regulatory submittal."

Arable brings a suite of services to offer the pharmaceutical and biotech industries.  With the addition of the Perform platform, Arable introduces CTMS and EDC software to complement their existing partnerships with GlobalSubmit and Quest Life Sciences.

Arable is announcing a 30 day free trial of their Perform platform to highlight the benefits to clinical organizations.  With the economic recovery continuing to affect pharma and biotech R & D budgets, Arable believes that the Perform software will save clinical organizations money and increase time to market.  Terms and conditions apply to the free offer.

Arable Corporation combines the right technology with our proven CRO servic
'/>"/>

SOURCE Arable Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. The Results are in: Users of BodyMedias Wearable Body-Monitoring Technology Lose 3 Times More Weight
2. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
3. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
4. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
5. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
6. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
7. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
8. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
11. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
(Date:7/29/2014)... , July 29, 2014 ... Austria will present data from a Phase ... aims to slow or stop Parkinson,s disease progression. The ... $ 1.5 million grant and will discuss the impact of ... When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... July 29, 2014   Abide Therapeutics ... to its board of directors. Thornberry was ... and Endocrinology for Merck & Co. Inc., where ... pipeline management in diabetes, osteoporosis, fertility and contraception. ... the program that resulted in the discovery of ...
Breaking Medicine Technology:Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
(Date:7/29/2014)... (PRWEB) July 30, 2014 Saint ... recently been awarded the Patient-Centered Medical Home 2011 ... National Committee for Quality Assurance. Only one out ... Level I, Level 2, or Level 3 recognition. ... in Patient-Centered Medical Home report faster access to ...
(Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now ... trends in garment fashion by providing graceful and sexy ... an all-inclusive array of sexy dresses , designed ... lot of customers take price into consideration. Worry no ... the purchase more affordable for all clients. , ...
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Diabetes is a ... is developed, blood sugar levels are increased, while the production ... produced by the pancreas and which is needed by the ... to overcome and can be very dangerous, as there are ... To learn more about this disorder and read a complex ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... found in foods, study shows , FRIDAY, Aug. 14 ... choline during pregnancy increases the risk of brain and ... focused on two types of neural tube birth defects ... condition in which the brain and skull don,t develop, ...
... named one of the top 10 hospital systems in the ... a leading business and professional information organization based in New ... systems outperformed their peers by a wide margin. They ... more lives, had fewer patient complications, and made fewer patient ...
... , ... On Oct. 9-10, 2009, CRSA will hold ... the organization. An estimated 300 surgeons will be in attendance ... applications for gastrointestinal, colorectal, vascular, transplant, endocrine, oncology and bariatrics. Those ...
... Mich., Aug. 14 Work and economy related stress is taking ... independent survey conducted by American Laser Centers, the largest provider of ... respondents who took part in the survey (47 percent) currently feel ... , , The physical toll of their ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... great progress being made with the experimental findings ... cure of Multiple Sclerosis not only in their ... unauthorized news link) , , http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090812/mtl_090812/20090812?hub=Health ...
... , , SAN FRANCISCO, Aug. ... few have success rates higher than 50 percent and none have been ... r al H e alth International (NHI), ... today, its Femmenessence line has been clinically proven to alleviate ...
Cached Medicine News:Health News:University Hospitals in Cleveland named one of the top 10 hospital systems in United States 2Health News:International Robotic Surgery Forum Launches In Chicago 2Health News:International Robotic Surgery Forum Launches In Chicago 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 2Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 4Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Medicine Products: